Oncotype DX ® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy
ConclusionsHigh Oncotype DX RS was associated with pCR after NCT in this national cohort of ER-positive, HER2-negative patients. Oncotype DX testing could help to identify patients most suited for NCT and should be considered for incorporation into the multidisciplinary decision-making process.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | HER2 | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy